Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Atryn Articles

Shin Poong and LFB set up joint venture to manufacture biotech products

11 January 2013

GTC Biothera agrees to go private for $0.30 a share

9 November 2010

Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII

18 January 2010

Lundbeck launches ATryn in USA

7 May 2009

GTC pursuing legal action against LEO

23 March 2009

GTC Bio gains $1M ATryn milestone

16 March 2009

FDA clears GTC's ATryn, first US-approved drug made from a transgenic animal

16 February 2009

FDA panel gives nod to GTC's antithrombin

19 January 2009

GTC's 3rd-qtr net loss narrows to $6.1M

17 November 2008

FDA accepts Ovation's ATryn BLA filing

13 October 2008

FDA priority review for GTC's Atryn

15 September 2008

GTC completes BLA filing for ATryn

18 August 2008

OVATION Pharma in-licenses GTC Bio's ATryn in a deal valued at up to $257M

30 June 2008

GTC's ATryn granted orphan status by FDA

17 December 2007

FDA fast-track for GTC's ATryn

10 September 2007

ATryn introduced at ISTH conference

26 July 2007

MA for GTC Bio's ATryn goes to Leo

8 January 2007

CHMP gives nod to GTC's ATryn, triggers $1M milestone

19 June 2006

GTC Bio restructures to support programs

9 February 2004

Showing 1-19 of 19 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS